Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera in Grade 2 and Grade 3 advanced GEP-NET
NCT03972488Phase 3Active, not recruiting
- Sponsor
- Advanced Accelerator Applications
- Start
- Jan 2020
- Primary completion
- Jul 2023
- Modality
- Peptides, Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Advanced Accelerator Applications. Started Jan 2020; status: active, not recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03972488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03972488.